Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Artavazd Arumov Ph.D
Principal
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Phil DiGiacomo
Principal
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Co-Founder and Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Will McConnell
Principal
Gary Rieschel
Founder and Managing Partner
James Shen
Venture Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Oscar Zhang
Principal
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Zhifeng Zhou
Managing Partner
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Phillip DiGiacomo Ph.D
Principal
Past deals in Asia
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Dearer Medical
Venture Round in 2024
Dearer Medical is a medical device company based in China that specializes in the development, production, and sales of eye-related products, particularly contact lenses. The company emphasizes research and development to create both practical and fashionable color contact lenses, catering to a diverse customer base. Through its innovative approach, Dearer Medical aims to enhance the user experience while addressing the aesthetic and functional needs of contact lens wearers.
XellSmart
Series B in 2024
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Shanghai Mufan Power
Series B in 2024
Mufan Power is a high-tech enterprise specializing in turbomachinery, focused on developing zero-carbon hydrogen power generation technologies. The company manufactures hydrogen gas turbines designed for various applications, including distributed energy systems, data centers, rail transit, marine power, vehicle propulsion, and energy storage peak shaving. Mufan Power also offers technical consultation and engineering services related to gas turbines, steam turbines, and other turbomachinery, having contributed to the design and development of significant national heavy equipment in China.
FXiaoKe
Venture Round in 2024
FXiaoKe is a Beijing-based company that specializes in cloud-based sales management solutions for Chinese businesses, particularly targeting small and medium-sized enterprises. Established in December 2011 by Luo Xu, the company provides a comprehensive platform that integrates field operation management, distribution chain management, and customer relationship management. FXiaoKe's software enables businesses to enhance their sales processes through a social interaction platform that merges features of dynamic customer relationship management with capabilities akin to enterprise WeChat. The platform supports collaboration across various sectors, including high-tech industries, corporate services, fast-moving consumer goods, agriculture, and large-scale manufacturing, facilitating efficient marketing, sales, and service operations. Additionally, FXiaoKe offers online office automation services that allow seamless information sharing between personal computers and smartphones, further enhancing customer management.
SinoUnited Health
Series D in 2024
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
Engitist
Series B in 2024
Engitist is a company based in Suzhou, China, that specializes in the research, manufacture, and sale of semiconductor optical measurement and testing equipment. Founded in 2018, Engitist offers a range of products including microscopic film measurement, optical defect detection, and optical linewidth measurement. The equipment is designed to provide high accuracy and reliability, enabling semiconductor manufacturers to effectively monitor product quality and enhance the sophistication of their semiconductor products. Engitist serves a global clientele, delivering high-quality solutions tailored to the needs of the semiconductor industry.
Alpha Biopharma
Series B in 2024
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.
DK Medtech
Series E in 2024
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
Dezhen Technology
Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.
Yanshengchao
Angel Round in 2024
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
Chunyu Yisheng
Venture Round in 2024
Chunyu Yisheng is a mobile application that enables physicians and their patients to communicate with each other. The application provides physicians with access to their patients’ medical records. Furthermore, it enables the patients to communicate and schedule appointments with the doctors. In addition, it offers reservation line treatment services to its users. Chunyu Yisheng was launched in 2011 by Rui Zhang and is based in Beijing.
Leapstack
Series C in 2023
Leapstack is an insurance technology company based in Shanghai, with additional offices in Beijing and Nanjing. Founded in February 2016, it focuses on developing big data artificial intelligence solutions tailored for commercial insurance companies and social security management agencies. The company's platform enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, anti-fraud measures, and compliance identification. By addressing inefficiencies in the industry, Leapstack aims to improve operational effectiveness and provide comprehensive data analysis and management tools for its clients.
Yanshengchao
Angel Round in 2023
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
Puanita
Series A in 2023
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Ailomics Therapeutics
Angel Round in 2023
Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is dedicated to developing innovative drugs for the treatment of immune diseases and tumors. The company utilizes a computational biology platform to analyze multi-omics data from patients, which aids in discovering novel drug mechanisms and targets that contribute to disease progression. Through this approach, Ailomics aims to enhance the understanding of complex diseases and advance the development of effective therapeutic solutions.
CuroVax
Series B in 2023
CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. It offers a range of vaccines, including a Freeze-Dried rabies vaccine for human use and an Influenza virus split vaccine, along with related logistics services. The company employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and antigen purification, vaccine testing, and mRNA vaccine development. CuroVax aims to provide safe and efficient products, contributing to the improvement of global health.
DK Medtech
Venture Round in 2023
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
Zeen Health
Series A in 2023
Zeen Health is a digital therapeutics company that specializes in providing personalized mental health services through a mobile application. Founded in 2019 and headquartered in Shenzhen, China, the company utilizes artificial intelligence technology to deliver evidence-based mental health solutions. By focusing on the individual needs of users, Zeen Health aims to improve mental wellness through innovative digital approaches.
1 Yong Cloud
Series B in 2023
1 Yong Cloud is a Beijing-based company founded in 2017 that specializes in developing a tumor diagnosis and treatment standardization platform. This platform is designed to assist physicians in creating personalized diagnosis and treatment plans for patients with tumor diseases. By collecting and translating medical data, 1 Yong Cloud aims to enhance the quality and consistency of medical care while rationalizing treatment expenses. The company's comprehensive data and system services support healthcare professionals in improving the overall effectiveness of tumor diagnosis and treatment.
Puanita
Pre Seed Round in 2023
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.
Ricoton
Series A in 2023
Ricoton specializes in the development and production of medical devices aimed at treating or preventing cerebrovascular diseases. Founded in 2011 and based in Hunan, China, the company manufactures an array of intervention devices, including microcatheters, guidewires, and various tools for ischemic stroke treatment. Their product offerings feature a comprehensive three-piece set that includes a micro guide wire, micro catheter, and support catheter for vascular access, as well as a thrombectomy stent and balloon guide catheter. Ricoton's innovative solutions provide a one-stop thrombectomy option for patients, enhancing the effectiveness of cerebrovascular interventions.
Allorion Therapeutics
Series B in 2023
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.
Xinchuangyuan Semiconductor
Series A in 2023
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.
SinoUnited Health
Series C in 2023
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
Biotree Technology
Series A in 2023
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.
Tlibrium
Angel Round in 2022
Tlibrium provides expertise in the technology promotion and application service industry. Tlibrium was founded in 2022 and was headquartered in Shanghai, China.
Bio-Link
Series A in 2022
Bio-Link is a drug development company established in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, focusing on the development and manufacturing of essential process equipment and consumables. These products are utilized in the production of vaccines, antibody drugs, cell therapy, gene therapy, and other biologics. Bio-Link's offerings encompass upstream cell culture, disposable dispensing reservoirs, downstream chromatography, ultrafiltration, and filtration, along with process development services. The company aims to deliver high-quality and innovative solutions that enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, there are indications that Bio-Link may explore wearable technology aimed at elderly care.
Sunny Dental
Series A in 2022
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a wide range of orthodontic and dental services. The company provides diagnosis and treatment for dental implants, children's dentistry, dental restorations, periodontal disease, and dental pulp issues. Additionally, it offers oral and maxillofacial surgery as well as invasive extraction services. Sunny Dental aims to deliver professional care in all aspects of dental health, catering to various patient needs.
PureVision
Series A in 2022
PureVision focuses on developing medical devices for ophthalmology. PureVision was founded in 2022 and was headquartered in Wenzhou, Zhejiang China.
PlusLife Biotech
Series A in 2022
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
Bitworx
Series A in 2022
Bitworx is a company based in Chengdu, China, specializing in product development and applications that leverage advanced algorithm and chip technology for communication, sensing, and detection. Currently, Bitworx is operating in stealth mode, which indicates that it is in the early stages of its business activities and may not yet be publicly disclosing its specific projects or technologies. The focus on communication and sensing technologies suggests a commitment to innovation in fields that require precise detection and data transmission capabilities.
Intellinosis
Angel Round in 2022
Intellinosis is a diagnostic company that focuses on developing molecular diagnostic reagents. Intellinosis is headquartered in Minhang District, China.
Dezhen Technology
Series A in 2022
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.
XellSmart
Series A in 2022
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Focallure
Series B in 2022
Focallure is a cosmetic company headquartered in Guangzhou, China, specializing in the development and manufacture of beauty products, particularly base makeup and cosmetics. The company leverages big data analysis to enhance its operations by analyzing consumer product preferences and social content trends. This data-driven approach allows Focallure to create innovative products that aim to provide users with a fresh makeup experience.
KouTech
Series A in 2022
KouTech develops surgical robots that can perform ophthalmic surgery, trans-gastroscopic, and general-purpose microsurgery. KouTech was founded in 2022 and was headquartered in Shanghai, China.
Prismlab China
Series C in 2022
Prismlab China Ltd. is a high-tech enterprise established in 2005, specializing in the development, production, and sales of high-speed light-curing 3D printers. The company integrates optical, mechanical, electrical technology, and computer software and hardware, along with photopolymer materials, to produce advanced rapid prototyping machines based on SLA technology. With a global presence, its products are distributed across over 50 countries and regions, earning recognition and acclaim from users worldwide for their performance and innovation.
Ailomics Therapeutics
Seed Round in 2022
Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is dedicated to developing innovative drugs for the treatment of immune diseases and tumors. The company utilizes a computational biology platform to analyze multi-omics data from patients, which aids in discovering novel drug mechanisms and targets that contribute to disease progression. Through this approach, Ailomics aims to enhance the understanding of complex diseases and advance the development of effective therapeutic solutions.
Norm Medtech
Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.
Tasogare
Series C in 2022
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
OriginCell
Series B in 2022
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Qingflow
Series B in 2022
Qingflow is a software-as-a-service platform based in the Minhang District of Shanghai, specializing in business workflow management. The platform allows users to create customized management systems by freely designing and combining various modules. This flexibility enables individuals and organizations to develop personalized business workflows tailored to their specific needs, all without requiring any programming skills. Qingflow's approach empowers users to effectively manage their operations and enhance productivity through a user-friendly interface.
Biotree Technology
Series A in 2022
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.
Resunbio
Series A in 2022
Resunbio provides micro-nano processing research and development precipitation. Resunbio is headquartered in Longhua, China.
Puanita
Angel Round in 2022
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.
Wayon
Funding Round in 2022
WayOn is a company based in Shanghai, China, specializing in electronic circuit protection and power semiconductor solutions for various industrial sectors. Established in 1996, WayOn offers an extensive range of products designed to ensure safety and reliability in electronic applications. Their offerings include PPTC, CPTC, and chip fuses for over-current protection, as well as TVS, thyristors, and ESD components for over-voltage protection. Additionally, the company provides thermal fuses for over-temperature protection and various power management components such as BMS, MOSFETs, and protection ICs. WayOn's products cater to diverse applications, including telecommunications, rechargeable batteries, IT equipment, automotive electronics, industrial machinery, and consumer electronics.
Yanshengchao
Seed Round in 2022
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
MediLink Therapeutics
Series B in 2022
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.
Wowjoy Technology
Series A in 2022
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.
Xiaoniao Kuaiyan
Series A in 2022
Xiaoniao Kuaiyan, headquartered in Beijing, China, offers home physical examination services that include regular health check-ups, tumor screenings, infection tests, chronic disease surveillance, and customized testing options for clients. In addition to these health services, the company also facilitates business cooperation between enterprises and provides customer service and professional training. Xiaoniao Kuaiyan is involved in formulating management procedures for quality inspection work and develops a product knowledge base to enhance its service offerings.
Eigencomm
Series C in 2022
EigenCOMM Ltd. is a Shanghai-based company established in 2017, specializing in the research, development, and sales of cellular network internet chips. The firm focuses on providing complete solutions for Internet of Things (IoT) ecosystems, particularly in the realm of smart home appliances. EigenCOMM's product line includes standard NB-IoT terminal chips, which ensure comprehensive coverage of cellular data connections and extended standby times, positioning the company as a key player in the IoT market.
Tungee
Series B in 2021
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
Sinogen Biopharma
Venture Round in 2021
Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.
Xinchuangyuan Semiconductor
Series A in 2021
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.
SUPERHEXA
Series A in 2021
Superhexa is a hardware company based in Beijing, founded on October 15, 2020, by Xia Yongfeng. It specializes in the development of personal consumer electronics, aiming to integrate technology seamlessly into everyday life. By focusing on innovation, Superhexa seeks to enhance the user experience and adapt to the evolving needs of consumers.
Clinflash Heathcare Technology
Venture Round in 2021
Clinflash is a leading provider of cloud-based solution and relevant professional service in filed of clinical development in China. Clinflash aims to help pharmaceutical companies improve R&D effectiveness and efficiency through providing first class IT solution and professional service.
Allorion Therapeutics
Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.
Cornerstone Robotics
Series B in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
GenLight Medical
Series B in 2021
Genlight is a company based in Hangzhou, China, that specializes in developing advanced treatment solutions for epilepsy and other neurological disorders. The organization focuses on innovative technologies in the field of brain science and neurosurgery, creating laser medical equipment designed to improve patient outcomes. Genlight's offerings include brain-computer control technology, deep brain nerve stimulation with full-cranial implantation, brain computer chips, and a minimally invasive surgery system guided by magnetic resonance. These high-tech solutions aim to provide patients with effective and cutting-edge surgical options for neurological conditions.
Zeen Health
Venture Round in 2021
Zeen Health is a digital therapeutics company that specializes in providing personalized mental health services through a mobile application. Founded in 2019 and headquartered in Shenzhen, China, the company utilizes artificial intelligence technology to deliver evidence-based mental health solutions. By focusing on the individual needs of users, Zeen Health aims to improve mental wellness through innovative digital approaches.
Qingflow
Series B in 2021
Qingflow is a software-as-a-service platform based in the Minhang District of Shanghai, specializing in business workflow management. The platform allows users to create customized management systems by freely designing and combining various modules. This flexibility enables individuals and organizations to develop personalized business workflows tailored to their specific needs, all without requiring any programming skills. Qingflow's approach empowers users to effectively manage their operations and enhance productivity through a user-friendly interface.
Genevide
Angel Round in 2021
Genevide is a biotech company founded in 2019 and based in Suzhou, Jiangsu, China, focusing on gene research and development. The company has developed a molecular enzyme cycle screening platform designed to address challenges in nucleic acid detection. Its key technologies include enzyme-mediated one-step sample processing and enzyme-mediated double exponential amplification, which facilitate efficient nucleic acid detection for researchers. Genevide aims to provide innovative solutions that make nucleic acid detection more accessible and effective.
XellSmart
Seed Round in 2021
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Wowjoy Technology
Series A in 2021
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.
PlusLife Biotech
Series A in 2021
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
Berry Oncology
Series B in 2021
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Neuro3 Therapeutics
Seed Round in 2021
Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.
SUPERHEXA
Seed Round in 2021
Superhexa is a hardware company based in Beijing, founded on October 15, 2020, by Xia Yongfeng. It specializes in the development of personal consumer electronics, aiming to integrate technology seamlessly into everyday life. By focusing on innovation, Superhexa seeks to enhance the user experience and adapt to the evolving needs of consumers.
Liangyihui
Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. operates an authoritative online education and information platform focused on oncology. Based in Shanghai, China, the company collaborates with numerous reputable hospitals and institutions, both domestically and internationally, to address the information asymmetry in the cancer field. Liangyihui provides a comprehensive range of educational materials related to tumor treatment, including medical cases, conference information, online courses, and research reports. This platform serves as a valuable resource for oncologists and aims to enhance public understanding of cancer, promoting scientific knowledge and supporting efforts to prevent and combat the disease.
Insight Lifetech
Series D in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
WeRide
Series C in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.
Hesai Technology
Series D in 2021
Hesai Technology is a company based in Shanghai, China, founded in 2014. It specializes in designing laser radar systems using smart sensing technology. The primary application of these systems is to facilitate autonomous driving by enabling car companies to monitor mixed gas composition and detect hazardous leaks. Additionally, Hesai Technology develops natural gas leak detection systems for industrial processes. Its LiDAR products are used in a variety of applications including advanced driver assistance systems (ADAS), autonomous vehicle fleets, last-mile delivery robots, street sweeping robots, and logistics robots. The company operates through two main segments: the LiDAR segment and the gas detection segment, with the former being the primary revenue generator.
Insight Lifetech
Secondary Market in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Data Transmission Group
Secondary Market in 2021
Data Transmission Group is an Internet technology group focusing on big data services in the press and publishing industry. Data Transmission Group is committed to the digital transformation and upgrading of big data services in the press and publication industry and the digital transformation and upgrading of the media industry, creating a digital content profit model with content providers as the main commercial value, changing the way users acquire and disseminate knowledge, and leading the Internet + upgrade of China's news and publications Replacement and industrial development direction. At present, the group has nearly 200 employees, most of whom are senior publishing, Internet, and software R&D personnel. They have a complete independent R&D system and have rich research results in mobile Internet technology, storage technology, data mining, and publishing integration.
Render
Series A in 2021
Render is a Chinese manufacturer of high-tech medical products and solutions. Render is a Shenzhen-based company that was founded in 2010.
Tungee
Series C in 2021
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
P&R Measurement Technology
Series C in 2021
P&R Measurement Technology Co., Ltd., founded in 2011 and headquartered in Zhuhai, China, specializes in the research, development, and supply of testing and automation solutions. The company caters to various industries, including motors, household appliances, consumer electronics, and energy power. With a strong emphasis on engineering signal processing and acoustic/vibration testing, P&R Measurement offers a range of custom and semi-custom engineering testing equipment, as well as data processing and finite element simulation analysis services. The company operates subsidiaries in Guangzhou, Suzhou, Hong Kong, and the United States, with additional offices in Qingdao, Hefei, Shunde, and Ningde, enhancing its capacity to serve a diverse clientele.
Tasogare
Series B in 2021
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
SinoUnited Health
Series C in 2021
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
CastBox
Series C in 2021
CastBox is a spoken audio platform founded in 2016 and based in Beijing, China, with additional offices in Hong Kong and San Francisco. The platform allows users to easily find, access, and enjoy a wide range of spoken audio content, including podcasts, on-demand radio, and audiobooks, across multiple devices such as mobile phones, desktops, and smart home devices. CastBox employs proprietary technology, including curated podcast recommendations and an in-audio deep search feature powered by natural language processing and machine learning. This technology enables the platform to deliver personalized listening experiences tailored to individual user preferences and habits. The service is available in multiple languages, making it accessible to a global audience.
Xizi Education
Series A in 2021
Xizhi Education (Beijing Xizi Education Technology Co., Ltd.) is a leading enterprise in artificial intelligence empowerment education. The headquarters is located in Zhizhi Street, Zhongguancun, which is known as the “China Silicon Valley”. As one of the key incubators of Tsinghua University, from the aspects of policy, capital and talents, it has been strongly supported by Tsinghua's three innovation and entrepreneurship platforms iCenter, Chuang+ and xlab, and won the honor of Zhongguancun High-tech Enterprise.
ZSHK Laboratories
Series A in 2021
ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.
Sincere Edu
Series A in 2021
Sincere Edu Inc. is an online education company based in Beijing, China, founded in 2016. It specializes in providing educational services focused on accounting and finance, including training materials for the CPA exam and subjects such as tax laws, economic principles, financial management, and auditing. The company aims to create a comprehensive learning platform that supports financial professionals throughout their careers by addressing their diverse educational needs. Sincere Edu emphasizes the importance of knowledge sharing and has developed a teacher training system to enhance the quality of its educational offerings, ultimately helping clients improve their professional skills and learning efficiency in the financial industry.
ET Healthcare
Series G in 2021
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various hospital settings, including pediatric care, intensive care units, and emergency rooms. The company has developed the Pylon Immunochemistry System, which integrates laboratory analysis with point-of-care testing to meet diverse immunodiagnostic needs, such as inflammation, cardiac function, fertility, infectious diseases, and tumor detection. Additionally, the Pylon BNP Immunoassay supports heart failure management by measuring B-type natriuretic peptide levels in plasma. ET Healthcare's products aim to bring the performance of traditional central lab analyzers to near-patient settings, addressing requirements for space, plumbing, and staffing. Headquartered in Palo Alto, California, the company also has offices in Shanghai and manufacturing facilities in Suzhou, China.
Unisound
Series D in 2021
Beijing Yunzhisheng Information Technology Co., Ltd., also known as Unisound, is a Chinese startup established in June 2012, specializing in intelligent voice and speech processing technologies. The company has developed proprietary speech recognition technologies and utilizes cloud computing to deliver a range of middleware and cloud platforms for speech recognition services. Unisound's offerings cater to both internet enterprises and individual users, providing professional solutions for voice recognition. The core technology team is composed of highly qualified professionals, with over 80% holding doctoral degrees and possessing extensive experience in voice recognition research and development. Additionally, Unisound focuses on Internet of Things (IoT) and artificial intelligence (AI) technologies, enabling efficient communication between users and machines through voice commands, thereby minimizing the need for manual input.
Alpha Biopharma
Series B in 2021
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.
Fucunbao
Series C in 2021
Fucunbao is an application that provides medical management solutions specifically designed for rural communities in China. It operates an online insurance and medical portal that enables users to pay for insurance online, create reimbursement plans, and identify disease types. The platform aims to enhance access to insurance and medical services for underserved populations. By leveraging government funding and resources, Fucunbao helps subsidize insurance and medical expenses, addressing the financial burdens that often result from healthcare challenges in these areas.
MediLink Therapeutics
Series A in 2021
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.
Hangzhou Weier
Series B in 2021
Hangzhou Weier Technology Co., Ltd, also known as Weier Science, specializes in the design and development of robots and software that enhance human-machine interaction. Founded in 2016 and headquartered in Hangzhou, China, the company operates within the augmented and virtual reality sectors. Weier Technology focuses on artificial intelligence and natural language processing to create customer service robots that assist e-commerce platforms. These robots can answer customer inquiries, generate customer profiles, and analyze data to improve service delivery, ultimately helping businesses better understand and engage with their clients.
XSKY Data Technology
Series E in 2021
XSKY Data Technology, based in Beijing, specializes in software-defined infrastructure products and services. It offers a range of storage solutions, including XCBS (cloud), XEBS (block), XEUS (unified), XEOS (object), and XEDP (unified data platform), catering to diverse sectors such as finance, enterprise, telecom, energy, and government. XSKY is a significant contributor to the open-source Ceph storage system, ranking top 3 globally. It partners with leading tech companies like Intel and Samsung, providing scalable, cost-effective storage solutions tailored for enterprise data center innovation.
Liangyihui
Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. operates an authoritative online education and information platform focused on oncology. Based in Shanghai, China, the company collaborates with numerous reputable hospitals and institutions, both domestically and internationally, to address the information asymmetry in the cancer field. Liangyihui provides a comprehensive range of educational materials related to tumor treatment, including medical cases, conference information, online courses, and research reports. This platform serves as a valuable resource for oncologists and aims to enhance public understanding of cancer, promoting scientific knowledge and supporting efforts to prevent and combat the disease.
Miaoshou Doctor
Series E in 2021
Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.
Erwan Technology
Series D in 2021
Erwan Technology is an online education provider based in Dalian Shi, Liaoning, China, specializing in financial investment education for Chinese middle-class families. Founded in 2016, the company offers a variety of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, aimed at equipping users with essential financial skills. With a focus on making financial education accessible, Erwan Technology has reached over 10 million middle-class students across 34 provincial administrative regions, establishing itself as the largest online investment education platform by user base and ranking among the top three platforms by revenue. The company’s mission is to enhance financial literacy by covering topics such as investment strategies, risk management, and wealth management.
Erwan Technology
Series E in 2021
Erwan Technology is an online education provider based in Dalian Shi, Liaoning, China, specializing in financial investment education for Chinese middle-class families. Founded in 2016, the company offers a variety of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, aimed at equipping users with essential financial skills. With a focus on making financial education accessible, Erwan Technology has reached over 10 million middle-class students across 34 provincial administrative regions, establishing itself as the largest online investment education platform by user base and ranking among the top three platforms by revenue. The company’s mission is to enhance financial literacy by covering topics such as investment strategies, risk management, and wealth management.
WeRide
Series B in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.
Kira Pharmaceuticals
Series B in 2021
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.
Abbisko Therapeutics
Series D in 2021
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
Cornerstone Robotics
Series A in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.